Background/Aims: The abnormally activated EGFR promotes tumor growth, invasion and metastasis. Current therapeutics targeting EGFR have markedly improved the clinical outcome, but they are limited in use due to transient efficacy, frequent administration, high cost and significant toxicity. Methods: We rationally designed a multiepitope immunogen against EGFR, named as DEGFRm. The immunogen is composed of an epitope peptide (EGFR265-283) and the extracellular domain III (EGFR334-505) of mouse EGFR. EGFR265-283 is grafted onto the translocation domain of diphtheria toxin (DTT), and EGFR334-505 is fused to C-terminal of DTT. Next, the immunogenicity and anti-tumor efficacies of DEGFRm vaccine were examined in mouse tumor models. Results: When...
BACKGROUND: A novel tyrosine kinase receptor EphA2 is expressed at high levels in advanced and metas...
Copyright © 2013 Mohan Karkada et al.This is an open access article distributed under theCreative Co...
a) C3H mice were left untreated or vaccinated with Lm-EGFRvIIIx5 twice separated by 14 days. 7 days ...
Dysregulated signaling via the epidermal growth factor receptor (EGFR)-family is believed to contrib...
Immunotoxins (ITs), which are toxin-fused tumor antigen-specific antibody chimeric proteins, have be...
Background: There is evidence of a relationship between epi-dermal growth factor (EGF) and tumor cel...
Her1 vaccine: It consists of immunizing patients with positive tumors for the epidermal growth facto...
The epidermal growth factor receptor (EGFR) is overexpressed in several epithelial tumors. Anti-EGFR...
Backgrounds: Epidermal growth factor (EGF) is a 53 amino acid polypeptide and its receptor EGFR is a...
Abstract The epidermal growth factor receptor variant III (EGFRvIII) is the most common variation of...
Epidermal Growth Factor Receptor (EGFR) has central role in cancer therapy because it causes tumour ...
A treatment strategy for cancer is the suppression of tumor growth by directing an immune response t...
Peptide-based vaccines are attractive approaches for cancer immunotherapy; but the suc-cess of these...
We report the generation of a chimeric monoclonal antibody (ch806) with specificity for an epitope o...
Peptide-based vaccines are attractive approaches for cancer immunotherapy; but the success of these ...
BACKGROUND: A novel tyrosine kinase receptor EphA2 is expressed at high levels in advanced and metas...
Copyright © 2013 Mohan Karkada et al.This is an open access article distributed under theCreative Co...
a) C3H mice were left untreated or vaccinated with Lm-EGFRvIIIx5 twice separated by 14 days. 7 days ...
Dysregulated signaling via the epidermal growth factor receptor (EGFR)-family is believed to contrib...
Immunotoxins (ITs), which are toxin-fused tumor antigen-specific antibody chimeric proteins, have be...
Background: There is evidence of a relationship between epi-dermal growth factor (EGF) and tumor cel...
Her1 vaccine: It consists of immunizing patients with positive tumors for the epidermal growth facto...
The epidermal growth factor receptor (EGFR) is overexpressed in several epithelial tumors. Anti-EGFR...
Backgrounds: Epidermal growth factor (EGF) is a 53 amino acid polypeptide and its receptor EGFR is a...
Abstract The epidermal growth factor receptor variant III (EGFRvIII) is the most common variation of...
Epidermal Growth Factor Receptor (EGFR) has central role in cancer therapy because it causes tumour ...
A treatment strategy for cancer is the suppression of tumor growth by directing an immune response t...
Peptide-based vaccines are attractive approaches for cancer immunotherapy; but the suc-cess of these...
We report the generation of a chimeric monoclonal antibody (ch806) with specificity for an epitope o...
Peptide-based vaccines are attractive approaches for cancer immunotherapy; but the success of these ...
BACKGROUND: A novel tyrosine kinase receptor EphA2 is expressed at high levels in advanced and metas...
Copyright © 2013 Mohan Karkada et al.This is an open access article distributed under theCreative Co...
a) C3H mice were left untreated or vaccinated with Lm-EGFRvIIIx5 twice separated by 14 days. 7 days ...